Evidence map›Paper›PMID 31049964›Full record

ArticleAllergy2019

miR-10a-5p is increased in atopic dermatitis and has capacity to inhibit keratinocyte proliferation.

Helen Vaher, Toomas Runnel, Egon Urgard, Alar Aab, Gemma Carreras Badosa, Julia Maslovskaja, Kristi Abram, Liisi Raam, Bret Kaldvee, Tarmo Annilo and 5 more

Open access · greenAbstract read
In one paragraph

Article in Allergy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. MicroRNAs in atopic dermatitis: A systematic review.Journal of cellular and molecular medicine · 2020
    Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. The Role of MicroRNA in the Pathogenesis of Atopic Dermatitis.International journal of molecular sciences · 2025
    Review
  8. The role of microRNAs in atopic dermatitis.Non-coding RNA research · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Epigenetic Mechanisms of Epidermal Differentiation.International journal of molecular sciences · 2022
    Review
  20. The trans-omics landscape of COVID-19.Nature communications · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Helen VaherInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Toomas RunnelInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Egon UrgardInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Alar AabInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.ORCID 0000-0001-7661-0284
Gemma Carreras BadosaInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.ORCID 0000-0003-2100-0221
Julia MaslovskajaInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Kristi AbramDepartment of Dermatology and Venereology, Dermatology Clinic, Tartu University Hospital, University of Tartu, Tartu, Estonia.
Liisi RaamDepartment of Dermatology and Venereology, Dermatology Clinic, Tartu University Hospital, University of Tartu, Tartu, Estonia.
Bret KaldveeDepartment of Dermatology and Venereology, Dermatology Clinic, Tartu University Hospital, University of Tartu, Tartu, Estonia.
Tarmo AnniloEstonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.
Eric R TkaczykDepartment of Veterans Affairs and Vanderbilt University Medical Center, Nashville, Tennessee.
Toivo MaimetsInstitute of Molecular and Cellular Biology, University of Tartu, Tartu, Estonia.
Cezmi A AkdisSwiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Davos, Switzerland.
Külli KingoDepartment of Dermatology and Venereology, Dermatology Clinic, Tartu University Hospital, University of Tartu, Tartu, Estonia.
Ana RebaneInstitute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.ORCID 0000-0001-6051-1361
University of Tartu · EETartu University Hospital · EEUniversity of Zurich · CHVanderbilt University Medical Center · US

Funding

Vanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9M
GVHD quantitative assessment in skin of Veterans post-HCTIK2CX001785 · VA · VETERANS HEALTH ADMINISTRATION · PI TKACZYK, ERIC R · 2019 to 2024
–
Centre of Excellence in Translational Medicine 1.01.2016-31.12.2018Christine Kühne-Center for Allergy Research and EducationCSRD VA IK2 CX001785Estonian Research Council IUT20-60Estonian Research Council MOBJD106Estonian Research Council PUT1465Estonian Research Council PUT1669European Union through the European Regional Development Fund 2014-2020.4.01.15-0012Leo Foundation LF17040NCI NIH HHS K12 CA090625
6 · The paper itself

Abstract

backgroundmiR-10a-5p has been shown to regulate cancer cell proliferation and invasiveness and endothelial cell inflammatory responses. The function of miR-10a-5p in the skin has not been previously studied. The aim of the current study was to examine miR-10a-5p expression, regulation, and function in keratinocytes (KCs) in association with atopic dermatitis (AD).

methodsThe expression of miR-10a-5p and its target genes was analyzed using RT-qPCR, mRNA array analysis, in situ hybridization, and immunofluorescence. The transfection of miRNA mimics, cell cycle distribution analysis, and luciferase assays was used to study miR-10a-5p functions in human primary KCs.

resultsmiR-10a-5p was found to be upregulated in lesional skin from patients with AD and in proliferating KCs. Array and pathway analysis of IL-1β-stimulated KCs revealed that miR-10a-5p inhibited many genes that affect cell cycle progression and only a few inflammation-related genes. Accordingly, fewer cells in S-phase and reduced proliferation were detected as characteristics of miR-10a-5p-transfected KCs. The influence of miR-10a-5p on cell proliferation was also evident in KCs induced by AD-related cytokines, including IL-4, IL-17, and IL-1β, as measured by the capacity to strongly suppress the expression of the proliferation marker Ki-67. Among AD-related putative direct target genes, we verified hyaluronan synthase 3, a damage-associated positive regulator of KC migration and proliferation, as a direct target of miR-10a-5p.

conclusionsmiR-10a-5p inhibits KC proliferation and directly targets hyaluronan synthase 3 and thereby may modulate AD-associated processes in the skin.

Indexed as

Gene Expression RegulationRNA InterferenceAdultCell CycleCell DifferentiationCell ProliferationCytokinesDermatitis, AtopicDisease SusceptibilityFemaleGene Expression ProfilingHumansKeratinocytesMaleMicroRNAsMiddle AgedCytokinesMicroRNAsMIRN10 microRNA, humanallergyatopic eczemacell cyclehyaluronic acidnoncoding RNA

Identifiers

PMID31049964
PMCPMC6817370
OpenAlexW2942762596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.